FNDC1 Facilitates Proliferation, Migration, and Invasion of Breast Cancer Cells Through Modulating Wnt/β-Catenin Pathway

Overview

Journal Biochem Genet

Specialty Molecular Biology

Date 2024 Dec 13

PMID 39671143

Authors

Guocai Fan

Chen Zhang

Affiliations

Soon will be listed here.

Abstract

Breast cancer is the most common malignant cancer and the leading fatal cancer in women around the world. Fibronectin type III domain-containing protein 1 (FNDC1) has been demonstrated to play crucial roles in various tumors. However, the function of FNDC1 in breast cancer remains to be addressed. Increased FNDC1 expression was found in breast cancer that is associated with individual cancer stages and lymph node metastasis through UALCAN analysis. Quantitative real-time polymerase chain reaction (qRT-PCR) and Western blot assays indicated that FNDC1 expression was up-regulated in breast cancer cells. The results of Cell Counting Kit-8 and colony formation assays indicated that FNDC1 promoted the proliferation of breast cancer cells. Moreover, FNDC1 knockdown suppressed xenograft tumor growth and inhibited the levels of FNDC1 and marker of proliferation Ki-67. Transwell assay demonstrated that FNDC1 promoted the migration and invasion of breast cancer cells. Importantly, mechanism analysis implied that FNDC1 promoted the Wnt/β-catenin signaling pathway. Notably, Wnt/β-catenin activation with LiCl significantly enhanced the proliferation and epithelial-mesenchymal transformation (EMT) inhibition effect of silencing FNDC1, whereas Wnt/β-catenin inhibition with XAV-939 significantly weakened the proliferation and EMT promotion effect of FNDC1. Analysis of β-catenin expression in the nucleus and cytoplasm showed that FNDC1 promoted β-catenin nuclear translocation. These data suggested that FNDC1 exerts its oncogene function through modulating Wnt/β-catenin signaling pathway. In conclusion, FNDC1 promotes cell proliferation, migration, invasion, and EMT through modulating Wnt/β-catenin signaling pathway in breast cancer, providing a new idea for the development of breast cancer therapeutic targets.

References

Aiyappa-Maudsley R, McLoughlin L, Hughes T . Semaphorins and Their Roles in Breast Cancer: Implications for Therapy Resistance. Int J Mol Sci. 2023; 24(17). PMC: 10487980. DOI: 10.3390/ijms241713093. View

Bakir B, Chiarella A, Pitarresi J, Rustgi A . EMT, MET, Plasticity, and Tumor Metastasis. Trends Cell Biol. 2020; 30(10):764-776. PMC: 7647095. DOI: 10.1016/j.tcb.2020.07.003. View

Basu S, Cheriyamundath S, Ben-Zeev A . Cell-cell adhesion: linking Wnt/β-catenin signaling with partial EMT and stemness traits in tumorigenesis. F1000Res. 2018; 7. PMC: 6144947. DOI: 10.12688/f1000research.15782.1. View

Cai W, Liu S, Liu Z, Hou S, Lv Q, Cui H . Downregulation of lung miR-203a-3p expression by high-altitude hypoxia enhances VEGF/Notch signaling. Aging (Albany NY). 2020; 12(5):4247-4267. PMC: 7093161. DOI: 10.18632/aging.102878. View

Chandrashekar D, Bashel B, Balasubramanya S, Creighton C, Ponce-Rodriguez I, Chakravarthi B . UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses. Neoplasia. 2017; 19(8):649-658. PMC: 5516091. DOI: 10.1016/j.neo.2017.05.002. View

Eble J, Niland S . The extracellular matrix in tumor progression and metastasis. Clin Exp Metastasis. 2019; 36(3):171-198. DOI: 10.1007/s10585-019-09966-1. View

Eissa S, Swellam M, el-Mosallamy H, Mourad M, Hamdy N, Kamel K . Diagnostic value of urinary molecular markers in bladder cancer. Anticancer Res. 2003; 23(5b):4347-55. View

Elanany M, Mostafa D, Hamdy N . Remodeled tumor immune microenvironment (TIME) parade via natural killer cells reprogramming in breast cancer. Life Sci. 2023; 330:121997. DOI: 10.1016/j.lfs.2023.121997. View

Herndon M, Ayers M, Gibson-Corley K, Wendt M, Wallrath L, Henry M . The highly metastatic 4T1 breast carcinoma model possesses features of a hybrid epithelial/mesenchymal phenotype. Dis Model Mech. 2024; 17(9). PMC: 11391819. DOI: 10.1242/dmm.050771. View

10.

Jiang H, Chu B, He J, Liu Z, Yang L . Expression and prognosis analyses of the fibronectin type-III domain-containing (FNDC) protein family in human cancers: A Review. Medicine (Baltimore). 2023; 101(49):e31854. PMC: 9750624. DOI: 10.1097/MD.0000000000031854. View

11.

Jin Y, Ye Y, Bao W, Tong Y, Ni S, Liu J . CACNA1B facilitates breast cancer cell growth and migration by regulating cyclin D1 and EMT: the implication of CACNA1B in breast cancer. J Recept Signal Transduct Res. 2020; 42(1):1-8. DOI: 10.1080/10799893.2020.1837871. View

12.

Kawiak A . Molecular Research and Treatment of Breast Cancer. Int J Mol Sci. 2022; 23(17). PMC: 9455640. DOI: 10.3390/ijms23179617. View

13.

Kuett L, Bollhagen A, Tietscher S, Sobottka B, Eling N, Varga Z . Distant Metastases of Breast Cancer Resemble Primary Tumors in Cancer Cell Composition but Differ in Immune Cell Phenotypes. Cancer Res. 2024; 85(1):15-31. PMC: 11694063. DOI: 10.1158/0008-5472.CAN-24-1211. View

14.

Li H, Zheng B . Overexpression of the Ubiquitin-Specific Peptidase 9 X-Linked (USP9X) Gene is Associated with Upregulation of Cyclin D1 (CCND1) and Downregulation of Cyclin-Dependent Inhibitor Kinase 1A (CDKN1A) in Breast Cancer Tissue and Cell Lines. Med Sci Monit. 2019; 25:4207-4216. PMC: 6568031. DOI: 10.12659/MSM.914742. View

15.

Li N, Miao Y, Shan Y, Liu B, Li Y, Zhao L . MiR-106b and miR-93 regulate cell progression by suppression of PTEN via PI3K/Akt pathway in breast cancer. Cell Death Dis. 2017; 8(5):e2796. PMC: 5520687. DOI: 10.1038/cddis.2017.119. View

16.

Lee K, Kuo T, Chou C, Hsu W, Lee W, Dai J . Upregulation of CD109 Promotes the Epithelial-to-Mesenchymal Transition and Stemness Properties of Lung Adenocarcinomas via Activation of the Hippo-YAP Signaling. Cells. 2020; 10(1). PMC: 7823273. DOI: 10.3390/cells10010028. View

17.

Liu J, Li D, Zhang T, Tong Q, Ye R, Lin L . SIRT3 protects hepatocytes from oxidative injury by enhancing ROS scavenging and mitochondrial integrity. Cell Death Dis. 2017; 8(10):e3158. PMC: 5680927. DOI: 10.1038/cddis.2017.564. View

18.

Liu Y, Chen W, Li W, Zhang M . Overexpression of FNDC1 Relates to Poor Prognosis and Its Knockdown Impairs Cell Invasion and Migration in Gastric Cancer. Technol Cancer Res Treat. 2019; 18:1533033819869928. PMC: 6751529. DOI: 10.1177/1533033819869928. View

19.

Mahmoud M, Sanad E, Elshimy R, Hamdy N . Competitive Endogenous Role of the LINC00511/miR-185-3p Axis and miR-301a-3p From Liquid Biopsy as Molecular Markers for Breast Cancer Diagnosis. Front Oncol. 2021; 11:749753. PMC: 8567754. DOI: 10.3389/fonc.2021.749753. View

20.

Mathenjwa G, Chakraborty A, Chakraborty A, Muller R, Akerman M, Bode M . Rationally modified SNX-class Hsp90 inhibitors disrupt extracellular fibronectin assembly without intracellular Hsp90 activity. RSC Med Chem. 2024; . PMC: 11403943. DOI: 10.1039/d4md00501e. View